

**PCSK9 INHIBITION AND LP(A) REDUCTION:  
ANOTHER PIECE OF THE PUZZLE?**

Angela Pirillo<sup>1,2</sup>, Alberico Luigi Catapano<sup>2,3</sup>

<sup>1</sup>Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, Milan, Italy

<sup>2</sup>IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy

<sup>3</sup>Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy

**Corresponding Author:**

Prof. Alberico L. Catapano

Department of Pharmacological and Biomolecular Sciences, University of Milan and IRCCS Multimedica

Via Balzaretti, 9 - 20133 Milan ITALY

Phone number: +39250318302

Fax number: +39250318386

e-mail: [alberico.catapano@unimi.it](mailto:alberico.catapano@unimi.it)

1 Lipoprotein(a) [Lp(a)] is an LDL-like particle in which apolipoprotein(a) is linked to apoB via a disulfide  
2 bond; epidemiologic and genetic studies indicate that elevated plasma levels of Lp(a) are a cardiovascular  
3 risk factor independent of LDL<sup>1</sup>. Furthermore, a strong association between elevated Lp(a) levels and calcific  
4 aortic valve stenosis has been shown, and Mendelian randomization studies have confirmed that Lp(a) is  
5 causally involved<sup>2</sup>. Owing the sequence homology with plasminogen, high Lp(a) levels are also believed to  
6 promote an athero-thrombotic condition via several mechanisms, including the inhibition of the fibrinolytic  
7 system and enhancement of tissue factor-mediated pathway<sup>3</sup>. Finally, it is now clear that elevated Lp(a)  
8 levels remain a cardiovascular risk factor even in patients with controlled LDL-C levels<sup>4</sup>, indicating that  
9 lowering Lp(a) levels should translate into a cardiovascular benefit.

10 Lp(a) levels are genetically determined, and primarily controlled by synthesis rather than catabolism<sup>4</sup>, and  
11 the fact that statins, despite their efficacy in reducing LDL-C levels by increasing the hepatic LDLR  
12 expression, have no or little effect on Lp(a) levels,<sup>5</sup> and that lipid-lowering drugs which act by reducing apoB  
13 synthesis or LDL assembly (including mipomersen and lomitapide) reduce Lp(a) levels<sup>6</sup> was somehow in  
14 line with expectations. It has therefore become quite puzzling that PCSK9 inhibitors, which also act by  
15 increasing LDLR expression, reduce significantly Lp(a) levels up to 30%<sup>7,8</sup>.

16 Kinetic studies are believed to be the gold standard in understanding whether a pharmacological  
17 intervention modifies the rate of synthesis or catabolism of a given protein, and this approach has  
18 successfully elucidated *in vivo* the mechanisms by which statins and other drugs affecting plasma  
19 lipoproteins act<sup>9,10</sup>. One of the complexities with lipoproteins is that the main protein of LDL, apoB, is mostly  
20 released in the circulation in VLDL and then eventually, by several remodelling passages, becomes a LDL;  
21 interpretation of the data via modelling of the kinetics is a must, with multiple compartments to fit the  
22 kinetic curves. A second level of complexity relates to Lp(a) owing the fact that the lipoprotein is assembled  
23 by associating to a LDL, making kinetic studies even more complex.

24 In the present issue, Watts and colleagues have investigated by kinetic studies the mechanisms by which  
25 evolocumab (a PCSK9 inhibitor) reduces Lp(a) levels<sup>11</sup>. They confirmed that the treatment with atorvastatin  
26 alone did not affect Lp(a) levels, with no changes in the fractional catabolic rate (FCR) or the production rate  
27 (PR) of Lp(a)-apo(a). Accordingly, the treatment with evolocumab or evolocumab+atorvastatin resulted in  
28 comparable reductions of Lp(a) levels (-33% and -38%, respectively)<sup>11</sup>. However, such reductions were  
29 achieved through two different mechanisms: when administered as monotherapy, evolocumab reduced the  
30 PR of Lp(a)-apo(a) without affecting its FCR<sup>11</sup>. In contrast, when given in combination with atorvastatin, the  
31 FCR of Lp(a)-apo(a) significantly increased, without alterations of its PR<sup>11</sup>. A previous study in which  
32 alirocumab was tested versus placebo reported different results: inhibition of PCSK9 reduced plasma Lp(a)  
33 levels by 18.7% (p<0.01), and this reduction was associated with a trend for an increase in the median FCR of  
34 Lp(a)-apo(a) (24.6%; P=0.09) and no changes in its PR<sup>12</sup>. The reason for this discrepancy is unclear; it should  
35 be noticed that the degree of Lp(a) reduction in this study was somewhat less<sup>12</sup>. Differences in the baseline  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 characteristics of subjects included in these two studies, including differences in Lp(a) baseline levels, age,  
2 BMI, and ethnicity<sup>11, 12</sup> may contribute in explaining these differences. Apo(a) isoform size may also play a  
3 role, as it may influence both production and catabolism of Lp(a) particles<sup>13</sup>.  
4  
5

6 *In vitro*, both LDL and Lp(a) compete with LDL for the binding to LDLR, but higher concentrations of the  
7 latter are required, suggesting that the two lipoproteins have different affinities for LDLR, being that of LDL  
8 higher. Thus, it can be assumed that, when LDL-C levels are massively reduced, Lp(a) clearance can increase  
9 due to a higher availability of “free” LDLR. Statin-induced inhibition of intracellular cholesterol synthesis by  
10 inducing the activation of SREBP-2, upregulates the expression of both LDLR and PCSK9 and the expression  
11 of LDLR receptor might be not high enough to support direct Lp(a) removal. By analogy in the presence of  
12 PCSK9 inhibitors, circulating PCSK9 is reduced, leading to a higher availability of LDLR for LDL  
13 internalization, which again may not be enough to efficiently remove Lp(a) particles. However, under these  
14 circumstances, evolocumab reduced Lp(a) levels by reducing the production of Lp(a)<sup>11</sup>. This observation is  
15 supported by a previous study showing that PCSK9 enhanced the secretion of Lp(a) from cultured  
16 hepatocytes, an effect that was blunted by alirocumab, without any effect on Lp(a) uptake<sup>14</sup>. This study could  
17 not demonstrate an involvement of LDLR in the uptake of Lp(a)<sup>14</sup>. It is intriguing to suggest an intracellular  
18 role for PCSK9 in modulating Lp(a) plasma levels; the mechanism, however, has not been addressed so far.  
19 When given in combination with a statin, the concomitant increase of LDLR expression and reduction of  
20 circulating PCSK9 leads to a further increased availability of “free” LDLR and to a massive decrease of LDL-  
21 C; this leads to a profound reduction of the high affinity ligand of LDLR (i.e. LDL), thus allowing the  
22 binding of a lower-affinity ligand (i.e. Lp(a)). This finding is supported by the observation that the reduction  
23 in Lp(a) levels was significantly correlated with reduction in LDL-C levels: there was a greater Lp(a) percent  
24 reduction in patients who achieved LDL-C  $\leq 40$  mg/dL than in those who achieved LDL-C  $>70$  mg/dL,  
25 supporting a relevant role of LDLR in the removal of Lp(a)<sup>7</sup>. One way to address this possibility would be to  
26 externally clamp LDL levels to higher values and then re-perform kinetics. A reduction of the FCR should be  
27 observed.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Alternative explanation may be based on the fact that experimental and clinical evidence suggests the  
47 involvement of additional receptors/pathways in the clearance of Lp(a)<sup>15</sup>. Evolocumab, although did reduce  
48 LDL-C levels only marginally in 2 HoFH patients carrying complete loss-of-function LDLR mutations,  
49 reduced significantly their Lp(a) levels despite the absence of LDLR<sup>16</sup>, indicating the possible involvement of  
50 other pathways perhaps also intracellular. Some additional receptors have been suggested as likely involved  
51 in Lp(a) clearance; among them, the two members of the LDLR family VLDLR and megalin/LRP2<sup>15</sup>;  
52 plasminogen receptors, scavenger receptor type B class I (SR-BI) and sortilin have been proposed as well<sup>15, 17</sup>.  
53 The role of these receptors in the catabolism of Lp(a) is still largely unexplored, as it is the possible  
54 involvement of PCSK9 in regulating their expression. An alternative explanation that deserves consideration  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 is that PCSK9 also binds to Lp(a)<sup>18</sup>, one could speculate that, in statin-treated patients, the increased amount  
2 of circulating PCSK9 leads to higher percent of Lp(a)-PCSK9 complexes, which in turn are recognized by the  
3 antibodies, promoting an alternative antibody driven removal pathway  
4  
5

6 Finally a word of caution on the methodology, although the careful nature of the work is appreciated, issues  
7 about the methodology and data analysis are still present. Isolating apo(a) and Lp(a) apo B is not an easy  
8 task and the studies of isotopic enrichment clearly depend on these processes; further the theoretical  
9 modeling with the different compartments also heavily depends on these data and small changes may  
10 preferentially favor a pathway *vs* another.  
11  
12  
13  
14  
15

16 In summary to date, the mechanisms by which PCSK9 inhibition reduces Lp(a) levels are unclear, and the  
17 conflicting results reported in the studies of Watts<sup>11</sup> and Reyes-Soffer<sup>12</sup> confirm the complexity of Lp(a)  
18 metabolism and the fact that biology is not as simple as we tend to believe, several regulatory pathways can  
19 be in place and dissecting their relative role quite challenging. Clearly we need future studies addressing  
20 those aspects to understand, by the use of appropriate *in vitro* and *ex vivo* experiments, the complex picture  
21 that kinetic studies suggest to us.  
22  
23  
24  
25  
26  
27  
28  
29

30 **Figure 1.** Possible mechanisms of statins and mAbs to PCSK9 on Lp(a) metabolism. LDLR seems to be  
31 involved in Lp(a) catabolism, but other receptor may also play a role. (A) Under physiological conditions,  
32 LDLR surface expression is regulated by the content of intracellular cholesterol and the amount of  
33 extracellular PCSK9. (B) Statins reduce cholesterol biosynthesis, leading to the upregulation of both LDLR  
34 and PCSK9. LDL-C levels are decreased. Under this condition, LDLR is not available for a lower affinity  
35 binding with Lp(a) as it is mainly engaged in the removal of LDL. Other receptors possibly involved in Lp(a)  
36 uptake might be controlled by PCSK9. The increased levels of PCSK9 may lead to an increased formation of  
37 PCSK9-Lp(a) (and/or LDL) complexes. (C) In the presence of anti-PCSK9 mAb, extracellular PCSK9 is  
38 sequestered; thus, LDLR is recycled to the surface and available for new binding. The reduction of PCSK9  
39 reduces the production of Lp(a) particles through several mechanisms. Lp(a)-PCSK9 complexes may be  
40 recognized by the anti-PCSK9 mAb, promoting an alternative removal pathway. (D) In the presence of statin  
41 and mAb to PCSK9, both LDLR expression and recycling are increased, leading to a massive reduction of  
42 LDL particles. This increases the number of free LDLR, which are thus available for the low affinity binding  
43 with Lp(a), leading to an increased Lp(a) uptake. Other receptors may contribute to the Lp(a) removal.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 1. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P,  
59 Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen  
60  
61  
62  
63  
64  
65

1 MR, Tokgozoglu L, Tybjaerg-Hansen A. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J* 2010;31(23):2844-2853.

2 2. Yeang C, Wilkinson MJ, Tsimikas S. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve  
3 stenosis. *Curr Opin Cardiol* 2016;31(4):440-450.

4 3. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular  
5 disease? *J Lipid Res* 2016;57(5):745-757.

6 4. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging  
7 Therapies. *J Am Coll Cardiol* 2017;69(6):692-711.

8 5. van Capelleveen JC, van der Valk FM, Stroes ES. Current therapies for lowering lipoprotein (a). *J*  
9 *Lipid Res* 2016;57(9):1612-1618.

10 6. Vogt A. Lipoprotein(a)-apheresis in the light of new drug developments. *Atheroscler Suppl*  
11 *2017;30:38-43.*

12 7. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A,  
13 Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA. PCSK9 inhibition-  
14 mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. *J*  
15 *Lipid Res* 2016;57(6):1086-1096.

16 8. Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ. Effect of  
17 Alirocumab on Lipoprotein(a) Over  $\geq 1.5$  Years (from the Phase 3 ODYSSEY Program). *Am J Cardiol*  
18 *2017;119(1):40-46.*

19 9. Lamon-Fava S. Statins and lipid metabolism: an update. *Curr Opin Lipidol* 2013;24(3):221-226.

20 10. Couture P, Lamarche B. Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism  
21 and beyond. *Curr Opin Lipidol* 2013;24(3):227-232.

22 11. Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR. Controlled  
23 study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on  
24 lipoprotein(a) particle kinetics. *Eur Heart J* 2018.

25 12. Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W,  
26 Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M,  
27 Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN. Effects of PCSK9 Inhibition  
28 With Alirocumab on Lipoprotein Metabolism in Healthy Humans. *Circulation* 2017;135(4):352-362.

29 13. Chan D, Barret PH, Marcovina SM, Coll Crespo B, Somaratne R, Rob S, Wasserman SM, Watts GF.  
30 Apolipoprotein(a) isoform size may influence the production and catabolism of lipoprotein(a) particles in  
31 men. *Atherosclerosis* 2017;263:e26.

32 14. Villard EF, Thedrez A, Blankenstein J, Croyal M, Tran TT, Poirier B, Le Bail JC, Illiano S, Nobecourt E,  
33 Krempf M, Blom DJ, Marais AD, Janiak P, Muslin AJ, Guillot E, Lambert G. PCSK9 Modulates the Secretion  
34 But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab. *JACC Basic Transl*  
35 *Sci* 2016;1(6):419-427.

36 15. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets.  
37 *Metabolism* 2013;62(4):479-491.

38 16. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase  
39 subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. *Circulation*  
40 *2013;128(19):2113-2120.*

41 17. Yang XP, Amar MJ, Vaisman B, Bocharov AV, Vishnyakova TG, Freeman LA, Kurlander RJ, Patterson  
42 AP, Becker LC, Remaley AT. Scavenger receptor-BI is a receptor for lipoprotein(a). *J Lipid Res*  
43 *2013;54(9):2450-2457.*

44 18. Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB,  
45 Lambert G, Tsimikas S, Fazio S. PCSK9 Association With Lipoprotein(a). *Circ Res* 2016;119(1):29-35.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

